Over the last decade, the cosmetic and nutraceutical industries have undergone a profound transformation. Consumers are no longer satisfied with innovative ingredients or sophisticated formulations alone; they increasingly demand clinically proven efficacy, transparency, and safety. At the same time, healthcare professionals, regulatory authorities, and retailers expect stronger scientific substantiation to support product claims. In this evolving landscape, the In & Out concept has emerged as one of the most promising approaches to skin health, combining topical skincare and nutritional supplementation to address skin ageing through complementary biological pathways.
From our perspective as a Clinical Research Organization (CRO), the real value of the In & Out strategy lies not simply in combining two products, but in demonstrating—through robust clinical research—that they work synergistically to produce measurable biological and clinical benefits. Today, innovation alone is no longer enough; scientific evidence has become the key differentiator.
The biological rationale behind the In & Out concept is straightforward. Topical cosmetics primarily target the epidermis and the dermal-epidermal junction, improving hydration, reinforcing the skin barrier, promoting epidermal renewal, and protecting against environmental aggressors collectively known as the exposome, including UV radiation, pollution, smoking, stress, and poor nutrition. Ingredients such as hyaluronic acid, retinoids, vitamin C, niacinamide, and biomimetic peptides have demonstrated significant benefits in improving skin appearance and function.
Conversely, nutraceuticals work from within. Through systemic circulation, bioactive compounds—including collagen peptides, antioxidants, vitamins, minerals, essential fatty acids, and plant extracts—reach the dermis, where fibroblasts synthesize collagen, elastin, and extracellular matrix components. These ingredients help modulate oxidative stress, chronic low-grade inflammation, cellular metabolism, and tissue repair, processes that cannot be effectively targeted by topical formulations alone.
Together, these two approaches provide a comprehensive strategy for maintaining skin integrity, slowing visible ageing, and supporting long-term skin function.
This integrated vision naturally aligns with one of today’s most important scientific trends: Healthy Aging and Skin Longevity. Rather than focusing exclusively on reducing wrinkles or improving hydration, the objective is to preserve the biological function of the skin, delay cellular senescence, maintain tissue homeostasis, and improve resilience against intrinsic and extrinsic ageing factors. Increasingly, skin is recognized as a mirror of systemic health, influenced by metabolism, nutrition, sleep quality, inflammation, the microbiome, psychological well-being, and lifestyle.
Another rapidly growing field supporting this evolution is Precision Nutrition. Future In & Out strategies are expected to move beyond “one-size-fits-all” supplementation by integrating individual biological characteristics, lifestyle, microbiome composition, metabolic status, and molecular biomarkers. Personalized nutritional interventions combined with targeted skincare represent one of the most exciting opportunities for the future of aesthetic medicine and preventive dermatology.
To scientifically validate these integrated approaches, clinical research must evolve beyond traditional efficacy studies. Modern clinical trials increasingly combine objective instrumental assessments with molecular biomarkers and patient-reported outcomes, providing a multidimensional understanding of product performance.
Systemic biomarkers obtained from blood, serum, or plasma have become fundamental tools for evaluating biological responses. Parameters such as high-sensitivity C-reactive protein (hs-CRP), interleukins (IL-6, IL-1β), TNF-α, oxidative stress markers including malondialdehyde (MDA) and 8-hydroxy-2′-deoxyguanosine (8-OHdG), antioxidant capacity, glucose metabolism, insulin resistance (HOMA-IR), lipid profiles, and collagen turnover biomarkers provide objective evidence that nutritional interventions influence pathways directly associated with healthy ageing. Emerging biomarkers related to NAD+ metabolism, cellular senescence, mitochondrial function, and biological age are also becoming increasingly relevant.
At the skin level, minimally invasive techniques such as Tape Stripping have transformed dermatological research. By sequentially collecting layers of the stratum corneum, researchers can evaluate structural proteins, natural moisturizing factors, epidermal lipids, inflammatory mediators, oxidative stress biomarkers, microbiome composition, RNA expression, and barrier function without the need for invasive biopsies. These molecular endpoints allow researchers to demonstrate biological changes long before they become clinically visible.
In parallel, advances in omics technologies—including transcriptomics, proteomics, metabolomics, lipidomics, and microbiomics—are opening entirely new possibilities for cosmetic and nutraceutical research. These approaches enable comprehensive analysis of thousands of genes, proteins, metabolites, and microbial populations simultaneously, providing unprecedented insight into product mechanisms of action. Future efficacy claims will increasingly rely on molecular pathway modulation rather than solely on visible cosmetic improvements.
Objective instrumental measurements remain essential. Technologies such as Corneometer®, Tewameter®, Cutometer®, Visioscan®, Corneofix®, VISIA®, three-dimensional imaging systems, and high-frequency ultrasound provide reproducible quantitative data on hydration, transepidermal water loss, elasticity, firmness, skin texture, epidermal renewal, dermal density, and wrinkle morphology.
However, clinical evidence cannot rely exclusively on laboratory measurements. Patient-centered outcomes remain equally important. Validated medical scales such as the Investigator Global Assessment (IGA) and Patient Global Assessment (PGA) provide standardized clinical evaluations, while questionnaires including the WHO-5 Well-Being Index, Hamilton Anxiety Rating Scale (HAM-A), Perceived Stress Scale (PSS), Positive and Negative Affect Schedule (PANAS), Pittsburgh Sleep Quality Index (PSQI), Leeds Sleep Evaluation Questionnaire (LSEQ), Fatigue Visual Analogue Scale (VAS), and Gastrointestinal Symptom Rating Scale (GSRS) assess dimensions increasingly associated with healthy ageing, including emotional well-being, stress resilience, energy, sleep quality, and digestive tolerance.
Looking ahead, one of the most transformative developments will be the integration of digital biomarkers and Artificial Intelligence (AI) into clinical research. AI-powered analysis of facial imaging, wearable devices, continuous physiological monitoring, and multimodal datasets will enable researchers to identify subtle response patterns, optimize study design, improve patient stratification, and generate predictive models of efficacy and safety. Rather than replacing clinical expertise, AI will enhance our ability to generate stronger, faster, and more meaningful scientific evidence.
Finally, efficacy must always be accompanied by rigorous safety assessment. Modern In & Out products require comprehensive evaluation through dermatological compatibility studies, irritation and sensitization testing, repeated-use trials, adverse event monitoring, and strict quality control of standardized raw materials and manufacturing processes. Scientific credibility depends not only on demonstrating benefits but also on ensuring an excellent safety profile.
From our experience as a CRO, the future of the In & Out concept will be defined by the integration of clinical outcomes, systemic biomarkers, skin biomarkers, omics sciences, advanced imaging, digital health technologies, and Artificial Intelligence within a single evidence-generation strategy. This multidisciplinary approach will enable companies to move beyond traditional cosmetic claims and build scientifically substantiated products that genuinely support skin health, longevity, and overall well-being. In an increasingly competitive market, scientific evidence is no longer simply an advantage—it is the foundation upon which the next generation of successful skincare innovation will be built.
Iván Parra
Commercial Director at Goya Innova
CONTACT
iparra@laboratoriogoya.com
